Vanguard Group Reports 0% Stake in Alnylam Following Internal Realignment
ALNYLAM PHARMACEUTICALS, INC.
Subscribe to track ALNY
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Vanguard Group Reports 0% Stake in Alnylam Following Internal Realignment
Company: Alnylam Pharmaceuticals Inc Form: SCHEDULE 13G/A | Filed: 2026/03/26 Significance: Low
Insider: The Vanguard Group Relationship: Institutional Manager
Transaction: • Type: Beneficial Ownership Update • Shares: 0 • Owned After: 0 • Percent of Class: 0%
Key Insight: Vanguard reports 0% ownership due to an internal realignment where subsidiaries now report separately. This does not necessarily indicate a market sell-off of the underlying assets.
Market Context: Alnylam is a Large Cap ($41.4B) pharmaceutical company. This filing is administrative in nature.
Comprehensive Analysis
SEC Filing Analysis: Alnylam Pharmaceuticals Inc
Executive Summary
- Trading Significance: Low
- Key Takeaway: The Vanguard Group reports 0% beneficial ownership due to an internal corporate realignment, not a liquidation of positions.
- Market Impact: Neutral - The change is administrative; subsidiaries will report holdings separately.
Company Information
| Field | Value |
|---|---|
| Company | Alnylam Pharmaceuticals Inc |
| CIK | 0001178670 |
| Industry | Pharmaceutical Preparations |
| Market Cap | $41.40 Billion |
Insider Information
| Field | Value |
|---|---|
| Name | The Vanguard Group |
| CIK | 0000102909 |
| Type | Institutional Advisor |
| Previous Status | >5% Beneficial Owner |
Transaction Details
| Field | Value |
|---|---|
| Form Type | SCHEDULE 13G/A (Amendment 10) |
| Event Date | 03/13/2026 |
| Shares Owned After | 0 |
| Percent of Class | 0% |
| Ownership Type | N/A |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Post-Transaction Ownership | 0 shares (0% of outstanding) |
| Materiality Assessment | Low (Administrative) |
Impact Evaluation
- Market Cap Context: As a $41.40B Large Cap company, changes in institutional reporting structures are common but rarely impact price discovery unless accompanied by actual volume.
- Transaction Significance: The filing explicitly states that Vanguard Group, Inc. no longer has beneficial ownership because subsidiaries now report on a disaggregated basis. This is a legal/compliance restructure.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: No shares were explicitly sold into the market based on this filing; the ownership was reallocated or redefined internally within Vanguard's corporate structure.
Volume & Sentiment
- Expected Volume Impact: Negligible.
- Sentiment Indicator: Neutral.
Additional Context
Transaction Notes
- Regulatory Note: The filing cites SEC Release No. 34-39538 (January 12, 1998) regarding the disaggregation of business divisions.
- Subsidiary Reporting: Future filings may appear from Vanguard subsidiaries individually rather than the parent group for this specific equity.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.